Blood neurofilament light chain levels are elevated in paediatric patients with multiple sclerosis and reduced under disease-modifying treatment

被引：0
|
作者：
Reinert, M. -C. [1 ]
Kropshofer, H. [2 ]
Barro, C. [3 ,4 ]
Wuerfel, J. [5 ,6 ]
Benkert, P. [3 ,4 ]
Michalak, Z. [3 ,4 ]
Brueck, W. [7 ]
Huppke, P. [1 ]
Tomic, D. [2 ]
Leppert, D. [2 ]
Kuhle, J. [3 ,4 ]
Gaertner, J. [1 ]
机构：
[1] Georg August Univ Gottingen, Univ Med Ctr Gottingen, Div Pediat Neurol, Dept Pediat & Adolescent Med, Gottingen, Germany
[2] Novartis Pharma AG, Basel, Switzerland
[3] Univ Basel, Univ Hosp Basel, Dept Med, Neurol Clin & Policlin, Basel, Switzerland
[4] Univ Basel, Univ Hosp Basel, Dept Biomed & Clin Res, Neurol Clin & Policlin, Basel, Switzerland
[5] Med Image Anal Ctr MIAC AG, Basel, Switzerland
[6] Univ Basel, Dept Biomed Engn, Basel, Switzerland
[7] Georg August Univ Gottingen, Univ Med Ctr Gottingen, Inst Neuropathol, Gottingen, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
基金：
新加坡国家研究基金会; 欧盟地平线“2020”;
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1793
引用
收藏
页码：1023 / 1023
页数：1
相关论文
共 50 条
  • [21] Prevalence of disease-modifying drug treatment gaps in patients with multiple sclerosis
    Joyeux, A.
    Kozma, C.
    Meletiche, D.
    Dickson, M.
    Bennett, R.
    JOURNAL OF NEUROLOGY, 2009, 256 : S163 - S163
  • [22] Neurofilament Light Chain Levels Are Associated with Disease Activity Determined by No Evident Disease Activity in Multiple Sclerosis Patients
    Szilasiova, Jarmila
    Rosenberger, Jaroslav
    Fedicova, Miriam
    Mikula, Pavol
    Urban, Peter
    Gdovinova, Zuzana
    Vitkova, Marianna
    Hanes, Jozef
    Stevens, Eva
    EUROPEAN NEUROLOGY, 2021, 84 (04) : 272 - 279
  • [23] Clinical features and disease-modifying therapy experience in paediatric multiple sclerosis
    Krupp, L
    Pardo, L
    Vitt, D
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S178 - S178
  • [24] Disease-modifying treatment of secondary progressive multiple sclerosis
    Hoffmann, Olaf
    Gold, Ralf
    NERVENARZT, 2021, 92 (10): : 1052 - 1060
  • [25] Serum neurofilament light chain levels as multiple sclerosis biomarker
    Abd-ElHady, Mohamed E.
    Hashish, Ehab
    Yassine, Imane
    Anani, Maha
    Negm, Mohamed
    PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2024, 28 (02) : 28 - 32
  • [26] Neurofilament light chain in the assessment of patients with multiple sclerosis
    Domingues, Renan Barros
    Peres Fernandes, Gustavo Bruniera
    Vilela de Moura Leite, Fernando Brunale
    Senne, Carlos
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2019, 77 (06) : 436 - 441
  • [27] Blood biomarkers for multiple sclerosis: neurofilament light chain and beyond
    不详
    EBIOMEDICINE, 2024, 104
  • [28] Adherence to disease-modifying therapies in patients with multiple sclerosis
    Koltuniuk, Aleksandra
    Rosinczuk, Joanna
    PATIENT PREFERENCE AND ADHERENCE, 2018, 12 : 1557 - 1565
  • [29] Monitoring of Subclinical Disease Activity by Serum Neurofilament Light Chain Levels in Multiple Sclerosis
    Uher, Tomas
    Schaedelin, Sabine
    Benova, Barbora
    Barro, Christian
    Bergsland, Niels
    Dwyer, Michael
    Tyblova, Michaela
    Kucerova, Karolina
    Benkert, Pascal
    Michalak, Zuzanna
    Leppert, David
    Naegelin, Yvonne
    Krasensky, Jan
    Seidl, Zdenek
    Vaneckova, Manuela
    Havrdova, Eva Kubala
    Kappos, Ludwig
    Zivadinov, Robert
    Horakova, Dana
    Kuhle, Jens
    Kalincik, Tomas
    NEUROLOGY, 2019, 92 (15)
  • [30] The Predictive Value of Neurofilament Light Chain Levels in Blood for Cognitive Impairment in Patients with Secondary Progressive Multiple Sclerosis
    Kuhle, Jens
    Kropshofer, Harald
    Barro, Christian
    Meinert, Rolf
    Haring, Dieter
    Leppert, David
    Dahlke, Frank
    Tomic, Davorka
    Kappos, Ludwig
    NEUROLOGY, 2019, 92 (15)
12345